An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.
Taha Al-Juhaishi, MD
Advertisement
Articles by Taha Al-Juhaishi, MD
Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.
Advertisement
Latest Updated Articles
CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025Published: June 9th 2025 | Updated:
- Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia
Published: May 5th 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Frontline Alectinib Upholds OS Benefit in Advanced ALK+ NSCLC
2
Episode 16: Anticipated ESMO 2025 Data That May Change GU Oncology
3
Lenvatinib/Everolimus Beats Cabozantinib in Phase 2 RCC Study
4
Tarlatamab Plus Chemo/IO Regimens Are Safe, Elicit Responses in ES-SCLC
5
